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1. INTRODUCTION 
Nanotechnology is a multi-disciplinary scientific field 
which should be undergoing explosive development. 
Parts of this field, development of nano-scale drug 
delivery devices are done. Nanoparticles have been 
developed as an important strategy to deliver 
conventional drugs, recombinant proteins, vaccines and 
most recently nucleotides 1. 
Nanotechnology is a rapidly growing field due to the 
ever-growing increase in technology and science. 
Because of the new inventions and the latest technology 
made available day by day, a lot of new avenues are 
bring opened which were impossible to even dream 
about in the yester-days. 
In the past few years nanotechnology has grown by leaps 
and bounds, and this multi-disciplinary scientific field is 
undergoing explosive development day by day with no 
limits 2-5. 
A complete list of the potential applications in 
nanotechnology is too vast and diverse to discuss, and its 
detail is too lengthy, but without doubt, one of the best 
values of nanotechnology will be in the development of 
new and effective medical treatments and different 
devices 6-10. 
Nanoparticles (NP) have been studied extensively as 
particulate carriers in several pharmaceutical and 
medical fields. Nanoparticles, can be used to provide 
targeted (cellular/ tissue) delivery of drugs, to sustain 
drug effect in target tissue, to improve oral 
bioavailability of solubilize drugs for intravascular 
delivery and to improve the stability of therapeutic 
agents against enzymatic degradation 11.  
These are the future benefits of the nanoparticles 
 It can protect drugs from degradation. 
 It can improve the physical properties of drug. 
 Reduction in number of doses required. 
 Make treatment a better experience and reduce 
treatment expenses. 
 Allow delivery of insoluble drugs. 
 It should not be loss their activity and therapeutic 
efficacy while in circulation. 
 Improve the oral bioavailability of the agents that are 
not effectively used orally. 
In the present study, we explored the potential of 
isoniazid nanoparticle in improving the oral 
bioavailability of isoniazid. 
ABSTRACT 
Although the part that we live in, is an age of creative technology and modernization, infectious diseases, like Tuberculosis  
(TB), still remain to be one of the greatest health challenges worldwide. The objective of this study was to load first line anti-
tubercular drug, isoniazid in chitosan nanoparticles in order to enhance its bioavailability and to reduce the dosing frequency. 
The isoniazid nanoparticles were prepared by Ionic gelation method with addition of suitable polymer (Chitosan) in acidic 
aqueous solution at various concentrations. The percentage yield obtained for the various formulations was 52-70 % which 
shows the suitability of ionic gelation technique for preparation of nanoparticles of isoniazid and the entrapment efficiency for 
the formulations F1-F5 was found to be in the range of 50-70% depending upon the polymer concentrations. It was observed 
that with an initial increase in polymer i.e. chitosan concentration entrapment efficiency increases, however it dips as 
concentration of chitosan is increased further because of increased solution viscosity which decreases the loading capacity of 
nanoparticles. After the SEM studies, it was observed that the formulation F3 nanoparticles was the best being spherical and 
more regular in shape and size range between 124-220 nm. The F3 isoniazid nanoparticle formulation had a mean particle size 
of 1.81 nm and zeta potential in (mV) is 52.4. During the in-vitro diffusion studies, it was observed that all the formulations 
show good control over the release of drug from the nanoparticles matrix. F3 formulation shows 87% drug release in 24 hours. 
It was observed that F3 follows the Korsmeyer Peppas model (r2 value=0.9864) indicating that the mechanism of drug release 
from the prepared F3 formulation is non fickian diffusion. 
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1.1 MAIN OBJECTIVE OF WORK: 
The aim of the present project work was to prepare and 
evaluate isoniazid nanoparticles for pulmonary drug 
delivery. 
Nanoparticle drug delivery system has received great 
attention through the last decade. Nanoparticle as a drug 
delivery system can deliver certain drug to systemic 
circulation in more convenient and effective way than 
possible with conventional dosage form. A drug 
incorporated nanoparticle can release the drug to greater 
extent with high concentration to the target site with low 
therapeutic dose. 
For pulmonary administration formulation includes 
biodegradable polymers nanoparticles, which are 
degraded in the body into carbon dioxide and water 
which are biocompatible. Poor soluble drugs 
bioavailability can be increased by reducing their particle 
size into submicron size. 
The main objectives of the project work were to develop 
a polymeric nanoparticle loaded with anti-tubercular 
drug to target the lungs with in a size range of 1-5µm. 
This provides control over the release pattern of drug. 
 To prepare polymeric nanoparticles of Isoniazid. 
 To optimize. 
 Pulmonary drug delivery using nanoparticles in the 
size range of 1-5 µm resulting in the effective 
distribution of nanoparticles in respiratory tract. 
 To extent the release of drug from the nanoparticles. 
 To improve the safety profile of the drug and 
localized stable drug concentration achieve and 
reduce the dosing frequency. 
2. MATERIALS AND METHODS 
2.1 Materials 
Isoniazid was obtained as a gift sample from Amsal 
Chemical Private Ltd, Gujrat, India. Chitosan was 
provided by Indian Research Products, Chennai, India. 
Acetic acid and Sodium tri-polyphosphate are obtained 
from Spectrum Reagents and Chemicals Pvt. Ltd, 
Cochin, India. All other reagents are used in this study 
were of analytical grade. 
2.2 Methods 
The isoniazid nanoparticles were prepared by Ionic 
gelation method with addition of suitable polymer 
(Chitosan) in acidic aqueous solution at various 
concentrations. Chitosan was dissolved in acetic acid 
aqueous solution at various concentrations. Drug was 
dispersed in chitosan solution and agitated over magnetic 
stirrer at room temperature for a period of thirty minutes. 
The Tri-polyphosphate aqueous solution with various 
concentrations was added drop wise to the above 
solution. Tri-polyphospate was added as a cross linking 
agent for the chitosan nanoparticles to achieve sustained 
drug release. Then the prepared nanoparticles were 
separated from the solution by sonication followed by 
centrifugation. 12 
2.2.1 Preparation of isoniazid nanoparticles 
Drug (Isoniazid) and Polymer (Chitosan) at various 
concentrations {0.25, 0.5, 0.75, 1, and 1.25 (w/v)} 
dissolved in Acetic acid {for all formulations the 
concentration of Acetic acid aqueous solution was 2 ml 
(v/v)} by help of magnetic stirrer and allowed to stand 30 
minutes and solution of drug and polymer was formed 
and this solution was kept over magnetic stirrer at 
specific room temperature. Various concentration of 
Sodium tri-polyphosphate solution is added in drop wise 
manner in prepared solution of drug and polymer and 
suspension of Isoniazid-Chitosan-Sodium tri-
polyphosphate nanoparticles was formed. It was kept for 
Sonication for 25 minutes. After sonication nanoparticle 
suspension was centrifuged at 19,000 RPM for 20 
minutes. The supernatant was discarded Pellets were 
resuspended in De-ionized water Followed by 
Sonification, centrifugation this process was repeated 
three times. The obtained particles were dried by using 
lyophilizer (VIRTIS FREEZE DRYER Maker-SP 
industries INP, Model-virtis advantage plus EL-85 and 
collected and store in well close container. 
2.2.2 Characterization of prepared nanoparticles 
All the method of characterization was important 
parameter for nanoparticle preparation. Several 
parameters which have to be considered in 
characterization are as follow. 
2.2.2.1 Fourier transformed infrared (FTIR) 
spectroscopic analysis  
FTIR spectra were recorded with a (Alpha-T Bruker IR 
instrument) IR spectrometer in range 400–4000 cm-1 
using a resolution of 4 cm-1 and 10 cm-1.Weighed amount 
of drug 3 mg was mixed with 12 mg of potassium 
bromide. The mixture was taken and compressed less 
than 10 ton pressures in a hydraulic press to form a 
transparent pellet. The spectra were recorded in order to 
evaluate the molecular states of micronized isoniazid and 
nano-isoniazid and also for the drug interaction studies 
of pure isoniazid, Chitosan and both. 
2.2.2.2 Evaluation of drug encapsulation 
2.2.2.2.1 Percentage yield 
The percentage yield of prepared nanoparticles of drug 
and polymer was calculated by using following equation 
Percentage yield =  
Total  weight  of  obtained  nanoparticle
Total  weight  of  drug  and  polymer
  X 100 
2.2.2.2.2 Entrapment Efficiency 
Entrapment efficiency was determined by crushed 
nanoparticles (1 mg Equivalent drug) add in 10 ml 
methanol; allow this suspension for 24 hrs. Then filter 
the suspension through (0.2 µm nylon filters) and 
supernatant collected was for assayed for drug content by 
UV spectroscopy (Shimadzu 1700, Japan) at the 
wavelength of 262 nm. 
The entrapment efficiency of nanoparticles for the drug 
was calculated by using the following equation  
Entrapment efficiency = 
Amount  of  drug  in  nanoparticles
Amount  of  drug  added  in  nanoparticles
X100 
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2.2.2.3 Scanning Electron Microscopy (SEM): 
The SEM analysis of prepared nanoparticles formulation, 
Scanning Electron Microscopy (SEM MU) was used for 
morphological studies. The formulation was scattered on 
an aluminium stub, the latter surface covered with clear 
double sided adhesive tape. . In order to obtain uniformly 
scattered sample the aluminium stab was tapped gently 
on its edge with a spatula. The particles were then coated 
with a 20nm layer of gold using a sputter coater on an 
argon atmosphere at 50 mA for 50 seconds. 
2.2.2.4 Measurement of Particle size and Zeta 
potential: 
Particle size distribution of isoniazid nanoparticle was 
determined by laser scanning technique using (Malvern 
Instrument) after appropriate dilution with KCl solution . 
The measurements were carried out in an aqueous 
solution of 0.1 N KCl. The mean particle size and zeta 
potential were calculated for each formulation 
maintained at 20 ̊ C. 
2.2.2.5 In-vitro release studies 
In-vitro release study of Isoniazid nanoparticles was 
performed on a USP Type II dissolution test apparatus 
(Electro lab, USP TDT 06P). A dialysis membrane 
pouches are made by sealing with clips used for filling 5 
mg isoniazid nanoparticles and attached on paddle by 
thread for dissolution test. The experiments were carried 
out at 37 ± 0.3°C at a rotation speed of 100 ± 2 rpm 
using 900 ml phosphate buffer (pH 7.4) as the release 
media, in order to simulate the condition in the lungs. A 
measure of 5 ml of the sample was withdrawn at 
appropriate time intervals (0, 1, 2, 4, 6, 8, 10, 12, 14, 16, 
18, 20, 22, and 24) and centrifuged at 10000 rpm for 5 
minutes. Supernatants were diluted suitably with 
methanol and absorbance of the resulting solution was 
measured at 262 nm in a UV spectrophotometer 
(Shimazdu UV-1700, Japan). The residue (after 
centrifugation) was redispersed in 1 ml of the fresh 
dissolution medium and replaced back into the 
dissolution apparatus. 13  
2.2.2.6 Mechanism of in-vitro drug release kinetics by 
using mathematical models: 
Various models were tested for investigate the mode of 
release explaining the kinetics of drug release form 
isoniazid nanoparticles, the release data were analyzed 
with the following mathematical models. To analyze the 
mechanism of the drug release rate kinetics of the dosage 
form, the obtained data were fitted into zero-order, first 
order, Higuchi’s and Korsmeyer-Peppas release model. 
Drug release rate kinetic of isoniazid nanoparticles was 
calculated by using DDS over, A Microsoft Excel Add-
in. 
3. RESULTS AND DISCUSSION 
3.1 Fourier transforms infrared spectroscopy: 
Fourier transform infrared (FTIR) spectrometry is a 
useful tool for identifying both organic and inorganic 
chemicals. It can be used to identify some components of 
an unknown mixture and can be utilize to analyse 
liquids, solids, or gases. FTIR Spectroscopy was used to 
ensure that no chemical interaction occurs between the 
drug and polymer used. This is given in Table 1: 
Table 1: FTIR Studies for drug and polymer 
S. NO. FTIR STUDIES 
1 Isoniazid (Drug) 
2 Chitosan (Polymer)  
3 Isoniazid + Chitosan 
FTIR Spectra interpretation the following results were 
obtained and shown in Table 2: 
Table 2: FTIR Vibrations for Isoniazid 
 S. NO. VIBRATIONS RANGE (cm
-1
) 
1 N-H2 3304 
2 C-H 2866 
3 C=O 1667 
4 N-H 1220 
5 C-O 1411 
6 C-N 1556 
7 N-N 1140 
 
The IR spectrum of the pure drug shows a broad 
absorption in near 3304 cm-1 due to presence of  (N-H2) 
amine group and other peaks C-H on 2867 cm-1, C=O on 
1667 cm-1, N-H on 1221 cm-1, this signifying that this 
structure is Isoniazid and its present in pure form.
 
 
Figure 1: FTIR Spectrum of pure Isoniazid 
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Figure 2: FTIR Spectrum of Chitosan 
 
Figure 3: FTIR Spectrum of Isoniazid-Chitosan 
 
The major characteristics peaks of the drug remain 
unaffected in the IR spectra for drug + excipient mixture, 
which clearly indicates that no interaction occurred 
between the drug and excipient. 
3.2 PERCENTAGE YIELD: 
Percentage yield of isoniazid nanoparticles was 
calculated by drug and polymer are collected after 
formulation. The % yields for formulations are given in 
Table 3: 
Table 3: Percentage yield of Isoniazid nanoparticles 
FORMULATION PRECENTAGE YIELD (%) 
F1 53.77 
F2 57.20 
F3 69.09 
F4 68.00 
F5 66.28 
According to the obtained result, the % yield of F3 
formulation is more than from all the formulations i.e. 
69.09 % and this result is shown in Figure 4:
 
 
Figure 4: Percentage yield graph of Isoniazid nanoparticle 
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3.3 ENTRAPMENT EFFICIENCY (E %): 
Entrapment efficiency gives the amount of drug 
entrapped in the nanoparticles. Entrapment efficiency (E 
%) of the prepared formulations influence by chitosan 
concentration and ionizing agent on the isoniazid 
entrapment in nanoparticles was evaluated. This 
calculation is shown in Table 4. According to the 
obtained result, the entrapment efficiency of F3 
formulation is more than from the entire formulations i.e. 
69.09 % and this result is shown in Figure 5. 
Table 4: Entrapment efficiency of Isoniazid 
nanoparticles 
FORMULATION ENTRAPMENT 
EFFICIENCY (%) 
F1 53.75 
F2 57.20 
F3 69.05 
F4 68.00 
F5 66.25 
 
 
Figure 5: Entrapment efficiency graph of Isoniazid nanoparticles 
 
The highest E% was found in formulations prepared with 
the lesser amount of chitosan i.e. F1. This is because the 
increase in chitosan concentration leads to increased 
solution viscosity that decreased the loading capacity of 
the nanoparticles as a consequence of the reduced drug 
solubilisation. Part of the drug was not dissolved during 
preparation process and/or it was probably lost from the 
nanoparticles during the washing steps.  
3.4 MEAN SIZE AND ZETA POTENTIAL FOR 
OPTIMIZED FORMULATION: 
The particle size (Malvern particle size analyzer) and 
zeta potential (Malvern zetasizer) were done for 
optimized F3 formulation in the size ranging from 1000 
nm to 4000nm. The size of nanoparticles was affected by 
the stirring time and the concentration of polymer. The  
mean particle size of the Isoniazid loaded nanoparticles 
were found to be 1.81 nm and Zeta potential of isoniazid 
loaded formulations were found to be 52.4 mV that 
shows that F3 formulation having high potential to 
conduct the surface charges with good stability. It can be 
observed in the Table 5. 
 
 
Table 5: F3 formulation with their particle size and Zeta Potential 
           Formulation         Mean Particle Size       Zeta potential (mV) 
                  F3               1.81 nm                   52.4 
  
According to this result, particle size and zeta potential are shown in Figure 6,7: 
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Figure 6: Measurement of particle size 
 
Figure 7: Distribution of zeta potential 
The F3 formulation of isoniazid nanoparticle parameter 
shows that, particle size of nanoparticle increases when 
the concentration of the chitosan increases. The result of 
Zeta potential in formulation F3 shows that it having 
high potential to conduct the surface charges with good 
stability. 
3.5 SCANNING ELECTRON MICROSCOPY: 
Shape and surface morphology of the isoniazid 
nanoparticles studied with optimized F1 and F3 
formulation was observed by scanning electron 
microscopy; SEM micrographs showed that 
nanoparticles were spherical and more regular in shape, 
the surface of the particle showed a characteristic 
smoothness, and that the particle size was in the 
nanometric range, as depicted by SEM. This was 
essential for pulmonary delivery of the drugs and was in 
the range of 1000 nm to 5000 nm in different 
formulation different chitosan concentration. These 
Scanning electron microscopy reports are shown in 
Figure 8, 9:                           
Scanning electron microscopy report: 
 
 
Figure 8: SEM result for F1 formulation 
(Observe nanoparticles in the range of 1000nm to 5000) 
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Figure 9: SEM result for F3 formulation 
(Observe nanoparticles in the range of 1000 to 5000nm) 
 
The result of SEM clearly shows that the F3 formulation 
of isoniazid nanoparticles was nearly spherical in nature, 
this is essential for pulmonary delivery (1-3 µm) of drug 
and the surface of the particle was smooth and that the 
particle size was in the nanometric range. 
3.6 IN-VITRO STUDIES OF ISONIAZID 
NANOPARTICLES: 
In-vitro release of Isoniazid Nanoparticles was 
determined using, as the release media, phosphate buffer 
(pH 7.4) in order to simulate the condition in the lungs. 
The in-vitro drug release studies for all five formulations 
of Isoniazid loaded nanoparticles were carried out in pH 
7.4 phosphate for 24 hrs. And these represented in Table 
6:
Table 6: In-vitro drug release profile of Isoniazid nanoparticle 
S. NO TIME (HOURS) C.D.R. (%) 
F1 F2 F3 F4 F5 
1 0 0 0 0 0 0 
2 1 3.01 3.27 2.93 3.22 3.30 
3 2 10.25 11.97 9.45 12.20 12.23 
4 4 17.63 22.21 15.45 21.52 21.19 
5 6 24.66 31.11 24.43 30.43 32.56 
6 8 33.26 40.12 32.22 39.40 41.20 
7 10 42.56 49.11 43.52 48.34 51.12 
8 12 48.62 57.15 52.24 57.28 60.17 
9 14 59.61 66.13 62.34 65.62 70.15 
10 16 68.20 74.46 67.21 74.67 79.13 
11 18 76.65 81.23 72.33 80.32 80.01 
12 20 84.55 87.31 74.23 86.02 87.43 
13 22 90.67 92.32 81.24 91.05 92.12 
14 24 96.26 96.64 87.52 96.03 96.24 
The results of in-vitro drug release for the various formulations are represented in Figure 10: 
 
F 
Figure 10: In-vitro drug release profile graph of Isoniazid nanoparticles 
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From the above results it was observed that, all the 
formulations show the ability to control drug release 
from the formulated nanoparticles. But F3 formulation 
shows best control release due to its smaller particle size 
which shows the suitability of the nanoparticles for 
achieving the goals of sustained drug release. And better 
shape, which shows that the formulation has been formed 
correctly, hence it’s has the ability to control drug 
release. In general the drug release from all formulation 
followed a steady pattern.  
3.7 IN-VITRO DRUG RELEASE KINETICS: 
The release kinetics should apply on best F3 formulation. 
Isoniazid nanoparticles are evaluated by fitted the 
obtained in-vitro release data into various kinetic models 
like zero order, first order, korsmeyer peppas and 
Higuchi equations. The drug release kinetic data of F3 
Isoniazid nanoparticles was shown in Table 7: 
Table 7: Kinetics of F3 formulation 
 
The results of in-vitro drug release kinetics for the 
optimized F3 formulation are represented in Figures 11, 
12, 13, 14: 
 
Figure 11: Zero order kinetics of F3 formulation. 
Zero order kinetics was applied on F3 formulation and 
R2 value is 0.9819. 
 
Figure 12: First order kinetics of F3 formulation 
First order kinetics was applied on F3 formulation and R2 
value is 0.7888 
 
 
Figure 13: Korsmeyer peppas kinetics of F3 
formulation 
Korsmeyer peppas kinetics was applied on F3 
formulation and R2 value is 0.9864. 
 
Figure 14: Higuchi kinetics of F3 formulation 
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 Higuchi kinetics was applied on F3 formulation and R2 
value is 0.984. 
It was observed that F3 follows the Korsmeyer peppas 
model R2 value were 0.9864 respectively which are 
higher than other models. So, it was concluded that this 
formulation follows Korsmeyer peppas kinetics, which 
releases drug in control manner and it is the ideal method 
of drug release to achieve pharmacological prolonged 
action. The values of release exponent (n) of F3 lies 
within of n = 0.5 to 1 have been observed, which are 
regarded as non-fickian diffusion mechanism. When a 
glassy hydrogel (film) is brought into contact with water 
or water-solvent mixture, the water diffuses into the film 
and the film expands resulting in swelling of the 
hydrogel. Diffusion involves migration of water into pre-
existing or dynamically formed species between 
hydrogel chains. Swelling of hydrogel involves larger 
scale segmental motion resulting ultimately increase in 
separation between film chains. Analysis of the 
mechanism of water or water-solvent mixtures diffusion 
into swellable polymeric system for chitosan films  
was found to be non-Fickian and could be described as 
anomalous which correlates with our studies as the 
calculated diffusion exponent is greater than 0.5 
indicating that the diffusion of solvent into the film was 
non-Fickian.14 Hence it is concluded that the mechanism 
of drug release from the prepared F3 formulation is non 
fickian diffusion.  
CONCLUSION 
Isoniazid nanoparticles were prepared by ionic gelation 
method and evaluation was done. The compatibility 
studies of Isoniazid and other excipients were carried out 
by FTIR studies to rule out the possibility of any 
interactions between the drug and the polymer. The 
peaks for major functional groups in drug and excipients 
spectra are reproducible when compared to the pure drug 
spectra. And this shows there is no interaction between 
the Isoniazid and other excipients used in the 
formulation. 
A total of five formulations were prepared by varying the 
concentration of chitosan. Particle size parameter shows 
that, the particle size of prepared Isoniazid nanoparticles 
increased with increase in the concentration of chitosan 
which can be attributed to increased solution viscosity. 
The entrapment efficiency for the formulations F1-F5 
was found to be in the range of 50-70% depending upon 
the polymer concentrations. It was observed that with an 
initial increase in polymer i.e. chitosan concentration 
entrapment efficiency increases, however it dips as 
concentration of chitosan is increased further because of 
increased solution viscosity which decreases the loading 
capacity of nanoparticles. And the result of mean particle 
size of the best F3 formulation is 181 nm and zeta 
potential of F3 formulation is 52.4 mV this result shows 
that F3 formulation having high potential to conduct the 
surface charges with good stability. SEM results clearly 
represents that the prepared Isoniazid nanoparticles were 
nearly spherical in nature, the surface of the particle was 
smooth and particles are in nanometric range. 
Prepared Isoniazid nanoparticles are evaluated for the 
total drug content, percentage yield and entrapment 
efficiency. All the formulations were able to control the 
release of drug. But while considering the zeta potential, 
particle size, SEM, in-vitro drug release and kinetic 
studies, it was concluded that F3 formulation is the best 
formulation among all the formulations.  
 It was concluded that this method of preparation 
Isoniazid nanoparticles is best which lead to better 
results like high entrapment efficiency, good percentage 
yield, high drug content and chitosan was a better choice 
of polymer for loading Isoniazid in it to prepare 
nanoparticles. 
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